Print  |  Close

Rodolfo E. Bordoni MD

Georgia Cancer Specialists - CenterPointe

Education and Training

Specialty and Certification

Medical Oncology / Board Certified

Clinical Trial Cancer Types

Bladder Cancer, Brain Cancer , Breast Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Multiple Primaries, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Prostate Cancer , Skin Cancer (Non-Melanoma), Solid Tumor

Affiliations

Northside Hospital
WellStar Kennestone Hospital

Active Clinical Trial Sites in Georgia

Georgia Cancer Specialists - CenterPointe

1100 Johnson Ferry Road
Suite 600
Sandy Springs, GA 30342
404-256-4777 (p)
www.gacancer.com

driving directions

Clinical Trials
Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Cancer Type: Bladder Cancer

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain Cancer

Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Cancer Type: Brain Cancer

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients with Residual Triple-Negative Basal-like Breast Cancer following Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Type: Breast Cancer

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Cancer Type: Breast Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Breast Cancer

A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Breast Cancer

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Cancer Type: Colon/Rectal Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type: Head and Neck Cancer

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Cancer Type: Lung Cancer

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type: Lung Cancer

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type: Lung Cancer

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
Cancer Type: Lung Cancer

A Phase II Study of Rucaparib in Patients with Genomic LOH High and / or Deleterious BRCA1 / 2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Cancer Type: Lung Cancer

A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Cancer Type: Lung Cancer

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Lymphoma

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Melanoma

Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Cancer Type: Melanoma

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Multiple Primaries

The National Myelodysplastic Syndromes (MDS) Study
Cancer Type: Myelodysplastic Syndromes (MDS)

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Non-Hodgkin Lymphoma

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Cancer Type: Skin Cancer (Non-Melanoma)

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Solid Tumor

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Unknown Primary

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Unknown Primary

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type: Unknown Primary

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Unknown Primary

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Unknown Primary

A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Unknown Primary


Northside Hospital Cancer Institute

1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355 (p)
www.northside.com

driving directions

Clinical Trials
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Cancer Type: Brain Cancer

Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Cancer Type: Brain Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Breast Cancer

A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Breast Cancer

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Cancer Type: Colon/Rectal Cancer

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type: Head and Neck Cancer

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Cancer Type: Lung Cancer

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type: Lung Cancer

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
Cancer Type: Lung Cancer

A Phase II Study of Rucaparib in Patients with Genomic LOH High and / or Deleterious BRCA1 / 2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Cancer Type: Lung Cancer

A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Cancer Type: Lung Cancer

Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Cancer Type: Melanoma

The National Myelodysplastic Syndromes (MDS) Study
Cancer Type: Myelodysplastic Syndromes (MDS)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Prostate Cancer

Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Cancer Type: Skin Cancer (Non-Melanoma)

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type: Unknown Primary

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Unknown Primary

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Cancer Type: Unknown Primary

A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Unknown Primary


WellStar Cobb Hospital

3950 Austell Road
Austell, GA 30106
770-732-4000 (p)
www.wellstar.org

driving directions

Clinical Trials


WellStar Douglas Hospital

8954 Hospital Drive
Douglasville, GA 30134
770-949-1500 (p)
www.wellstar.org

driving directions

Clinical Trials


WellStar Kennestone Hospital

677 Church Street
Marietta, GA 30060
770-793-5000 (p)
www.wellstar.org

driving directions

Clinical Trials


WellStar Paulding Hospital

2518 Jimmy Lee Smith Parkway
Hiram, GA 30141
470-644-7000 (p)
www.wellstar.org

driving directions

Clinical Trials

Active Clinical Trial Site Locations:

**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.